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Summary When mitozolomide was administered i.p. to mice, drug disposition appeared to fit a simple, one-
compartment kinetic model with an elimination half-life of < 1 h. The disposition of mitozolomide in mice
bearing the ROS osteosarcoma, also followed a first-order process but in this case the elimination of the drug
was significantly faster from plasma, liver, lung and kidney tissue compared to the elimination half-life of the
drug from the same tissues of mice without tumour (P<0.05).
Mitozolomide was rapidly and extensively distributed into tissues, including the tumour. Mitozolomide was
not concentrated in any particular tissue although the brain contained the lowest drug concentration
compared to any tissue studied. After 4h following administration, mitozolomide could not be measured in
plasma or tissues.
AUC values calculated from mitozolomide concentration versus time profiles in plasma, liver and kidney
homogenates were 27-29% lower in mice pretreated with phenobarbitone compared to those values obtained
from mice administered saline only, (P<0.02). Since phenobarbitone is known to induce liver microsomal
enzymes, it is possible that hepatic metabolism is involved in the degredation of mitozolomide.
Mitozolomide (8-carbamoyl-3-(2-chloroethyl) imidazo
[5, 1-d]-1, 2, 3, 5-tetrazin-4-(3H)-one (Figure 1) is a
novel antitumour agent (Stevens et al., 1984) with
significant activity against a wide range of murine
tumours (Hickman et al., 1982). It has completed
Phase 1 testing and is currently undergoing Phase
II clinical evaluation.
We have studied the disposition of mitozolomide
in the plasma and tissues of mice bearing the ROS
osteosarcoma and we therefore have the
opportunity to investigate the effect of the presence
of tumour on mitozolomide pharmacokinetics.
It is proposed that the cytotoxicity of
mitozolomide is mediated via its breakdown
product, MCTIC (5-[3-(2-chloroethyl) triazen l-yl]-
imidazole-4-carboxamide) (Horgan & Tisdale, 1984)
by the formation of interstrand cross-links with
DNA in a similar manner to that described for the
chloroethylnitrosoureas (Gibson et al., 1984a,b).
Analysis of the breakdown products in vitro
(Stevens et al., 1984) suggests that mitozolomide
chemically decomposes via nucleophilic attack to
yield the chloroethyltriazine, MCTIC (Figure 1).
The results presented in this paper suggest that
although chemical hydrolysis is the significant
decomposition mechanism, there are other factors
which influence the degradation of mitozolomide to
MCTIC. Furthermore, in a previous study of the
antitumour activity of mitozolomide, Workman and
Lee (1984) showed that phenobarbitone pre-
treatment reduced the activity of mitozolomide
against the KHT mouse sarcoma. It is interesting in
this context that hepatic metabolism was shown to
increase the biotransformation of 1-(2-chloroethyl)-
1-nitrosourea (CCNU) and 1, 3-bis(2-chloroethyl)-1-
nitrosourea (BCNU), thereby reducing the
antitumour activity of these chloroethylnitrosoureas
(Levin et al., 1979).
We studied the plasma and tissue disposition of
mitozolomide in mice pretreated with pheno-
barbitone in order to elucidate a possible
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Figure 1 Potential decomposition pathway of mito-
zolomide.
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pharmacokinetic explanation for the reduced
activity of the drug, in a similar experiment to that
performed by Levin et al. (1979) with BCNU.
Materials and methods
Tumour implantation
Female AKR mice (20-25g) were implanted with
approximately 1mm3 pieces of the Ridgeway
Osteogenic Sarcoma (ROS) s.c. in the left flank
whilst under light ether anaesthesia.
Drug administration
Mitozolomide was supplied by Professor M.F.G.
Stevens, Department of Pharmaceutical Sciences,
University of Aston, Birmingham, UK. For
injection, mitozolomide was dissolved in dimethyl-
sulphoxide/saline (1:5), and 10mgkg-1 was
administered i.p.
Phenobarbitone and pentobarbitone were
obtained from Sigma Chemicals, UK. Both drugs
were dissolved in sterile saline and 80mgkg-1 was
administered i.p. on 7 consecutive days. Control
mice within the same experiment received saline
only. Mitozolomide was administered 8 days after
the start of barbiturate pretreatment.
Assay ofdrug
Plasma and tissues were prepared for HPLC
analysis in the following manner. Mice were
anaesthetised using a halothane/N20/02 mixture
and 0.7-0.9ml blood samples were obtained by
cardiac puncture at the following time points: 0,
0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.Oh after drug
administration. Plasma and tissues were obtained
from tumour-bearing mice within the same
experiment at the following times: 0, 0.25, 0.5, 1.0,
2.0, 3.0, 4.0h after administration of mitozolomide.
Plasma and excised tissues (tumour, liver, kidney,
lung, muscle, spleen and brain) were immediately
frozen at -20°C until required for analysis.
Tumour weight after excision was -1g. The tissues
were sonicated (Heat systems-ultrasonics sonicator)
for between 10-30sec to yield 10-20%
homogenates in distilled water (pH <5). Oneml
tissue homogenate or 25041 plasma were used for
the drug assay.
Mitozolomide was measured in plasma and
tissues by HPLC as described previously (Slack &
Goddard, 1985). Briefly, mitozolomide was extracted
from acidified plasma and tissue samples with
ethyl acetate using as the internal standard [3-(2-
hydroxyethyl)-1, 2,3-benzotriazin-4(3H)-one] which
was synthesised by Mrs G.U. Baig, Department of
Pharmaceutical Sciences, Birmingham, UK. The
organic layer was evaporated under a stream
of nitrogen and the residue was redissolved
using 50% methanol in 5% acetic acid.
A Waters 100mm by 5mm pBondapak cartridge
(IOM particle size, C1, ) was used with a C18 pre-
column. An isocratic mobile phase of 30%
methanol in 5% acetic acid was pumped at a
constant flow rate of 1 mlmin 1 using a Waters
(Waters Associates, Northwich, UK) 6000K pump.
The injection volume was between 5-20Ml and
detection was at 325nm using a Waters Lamda-
max 480LC spectrophotometer.
The concentration of mitozolomide was deter-
mined from peak height ratios of mitozolomide to
internal standard. Calibration curves were con-
structed by the addition of mitozolomide to plasma
or tissue homogenate and were linear between 0.1-
204gml-1 (r>0.998).
Extraction reproducibility of mitozolomide from
plasma and tissues was between 84% (tumour) and
98% (spleen) with a coefficient of variation for
replicate samples of <10%. The detection limit of
the assay was 20ngml1 (1 ng on-column).
Pharmacokinetics
The mitozolomide concentration versus time curves
obtained from plasma and tissues of mice
pretreated with phenobarbitone were not considered
for pharmacokinetic modelling because of the
variable concentrations of drug in the late
disposition phase (see Figure 3a,b). All other
pharmacokinetic profiles of mitozolomide best
fitted a one-compartment, kinetic model (r>0.98
after linear regression analysis).
Pharmacokinetic parameters were estimated using
the interactive computer program, STRIPE
(Johnson & Woolward, 1983). Elimination half-life
(tl/2) was calculated from the equation
tl/2=ln2/k, where k is the elimination rate
constant given by the slope of ln plasma
concentration versus time. AUC from time 0 to the
final time t was estimated by the trapezoidal
method. The remaining AUC from t-oo was
estimated from the equation AUC (t-oo)=CJk,
where C, is the blood concentration at t.
Estimation ofprotein binding ofmitozolomide
Plasma obtained from mice, 3h after administration
of 10mgkg-I mitozolomide, was used to determine
the protein free fraction of mitozolomide.
Preparation of a protein free filtrate was achieved
using a Centrifree filter system (Amicon
Stonehouse, UK). A 100 u1 plasma sample was
centrifuged in a Centrifree tube at 2,000g for
20min at 4°C and the concentration ofDISPOSITION OF MITOZOLOMIDE IN MICE 93
mitozolomide in the ultrafiltrate was estimated.
Protein binding (PB) was calculated from:
concentration in ultrafiltrate
concentration in whole plasma
100%
Results
Plasma and tissue disposition of mitozolomide in
female AKR mice appeared to follow a simple, one-
compartment kinetic model (Figure 2) with an
elimination half-life of <1 h (Table I). A one-
compartment model could also be applied to the
plasma disposition of mitozolomide in BALB/c
mice and peak levels were reached within 10min
(Goddard & Slack, 1985).
As predicted by plasma pharmacokinetics,
mitozolomide was rapidly and extensively
distributed to mouse tissues and AUC values
calculated from mitozolomide concentration versus
time profiles ranged from 6.09 ug. h.g-1 for the
brain to 21.7 ug.h.g-1 for the liver. Although the
liver had the highest drug levels, the rates of decline
of mitozolomide in tissues were similar at all
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sampling times. In fact, between 0.5 and 2.0h, all
ratios of tissue to plasma concentrations of mito-
zolomide ranged from 0.50 to 1.19.
Mitozolomide is relatively lipophilic (log
P=0.388, M&B physical-chemical report PDU 30,
1984), and we have found mitozolomide to be only
moderately bound (67.1+1.6%) to plasma proteins
in mice. Therefore, it is probably not surprising
that appreciable concentrations of the drug were
found in the brain. Significant concentrations of
mitozolomide were also found in tumour tissue
(Figure 2).
The plasma, liver, lung and kidney elimination
half-life of mitozolomide in mice bearing the ROS
osteosarcoma was significantly less than respective
values obtained from non-tumour-bearing mice
(Figure 2; Table I). Values for elimination half-life
obtained from muscle and spleen homogenates were
also less in tumour-bearing mice compared to
control animals, but this difference was not
significant (Table I). The body weight of mice with
tumour did not appreciably change compared with
control animals and therefore the altered
disposition of mitozolomide was not due to
cachexia.
The AUC values calculated from mitozolomide
b
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Figure 2 Plasma and tissue concentrations of mitozolomide in non-tumour-bearing mice (a) and in mice
bearing the ROS tumour (b). The data shown were obtained from animals within the same experiment.
Experimental points represent mean values obtained from at least 4 independent experiments. For individual
experiments, replicate mice were used for each sampling time. ((A) liver; (-) lung; (0) plasma; (0) tumour;
(CI) brain).
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Table I Mitozolomide elimination half-life (h)
Tissue Tumour-bearing (ROS) Non-tumour bearing t-test (P)
Plasma 0.555+0.106 0.725+0.039 <0.02
Liver 0.639+0.027 0.731 +0.040 <0.005
Lung 0.573 +0.095 0.747+0.094 <0.02
Kidney 0.653+0.045 0.727+0.010 <0.05
Muscle 0.585+0.056 0.655+0.044 NS
Spleen 0.534+0.126 0.582+0.020 NS
Brain 0.602+0.026 0.576+0.057 NS
Tumour 0.793+0.098
Data represents mean values (±s.d.) from at least 4 independent experiments.
concentration versus time profiles were less for
plasma and some tissues in tumour bearing mice
(e.g. 16.7+4.9pg. h.ml-1 for plasma and
20.3 + 5.1 ug . h . g-1 for liver) compared to control
animals (20.1 +0.8 pgg. h . ml -1 for plasma and
21.7+2.lpg.h.g- 1 for liver). However, this
difference was not significant.
The disposition profiles of mitozolomide
obtained from mice pretreated with phenobarbitone
are shown in Figure 3a, b and demonstrate a
marked difference compared to those concentration
versus time profiles calculated from mice receiving
saline alone. AUC values obtained from pheno-
barbitone treated mice were significantly less than
those values from control animals (Table II).
Therefore, the reduction of mitozolomide
antitumour activity (Workman & Lee, 1984)
coincides with a decrease in the plasma and tissue
levels of the drug after administration of pheno-
barbitone. A 17% increase in liver weight compared
to control mice was found in those animals
receiving phenobarbitone (P<0.0005) which is
consistent with enzyme induction. However, AUC
values calculated from mice pretreated with another
barbiturate, pentobarbitone, were virtually identical
to mice treated with saline (Figure 3c,d) and a
significant increase in liver weight was not
observed.
Discussion
After i.p. injection, mitozolomide was rapidly
distributed to all tissues studied; the highest drug
concentrations being in those tissues with a large
blood volume (e.g. liver) or a high blood flow (e.g.
kidneys). Actual measurements of tissue concen-
trations of mitozolomide agree with the con-
clusions inferred from plasma pharmacokinetics
which imply rapid distribution of mitozolomide
throughout total body water. Since appreciable
amounts of mitozolomide are able to penetrate the
blood brain barrier, this drug may offer an
advantage over existing clinical agents to which the
brain is relatively impermeable.
The variable concentrations of mitozolomide seen
during the late disposition phase of the drug after
phenobarbital pretreatment is a puzzling obser-
vation. The manifestation of secondary peaks in
the declining concentration versus time curve for
plasma mitozolomide has also been observed for
the plasma disposition of cisplatin in patients
(Vermorken et al., 1984). These authors attributed
the increase in plasma concentrations of cisplatin to
enterohepatic circulation. However, recycling of
mitozolomide is unlikely. Although mitozolomide
may be excreted via the bile the drug is probably
not reabsorbed in the small bowel because it
Table II Effect of phenobarbitone on the disposition of mitozolomide
AUC O-4h (ug.h.ml-1 or g-1)
Phenobarbitone
pretreated Saline controls T-test (P)
Plasma 8.14+0.81 11.39+ 1.65 <0.01
Liver 9.52+ 1.51 13.43+ 1.42 <0.005
Kidney 9.26+1.04 12.57+ 1.02 <0.002
Data represents mean values (±s.d.) from at least 3 independent experiments.DISPOSITION OF MITOZOLOMIDE IN MICE 95
b a
1 2 3 4
I
0 1 2 3 4
d
I
2 3
Q\
0
1 2 3
Time (h) after administration
Figure 3 Effect of phenobarbitone (a, b) and pentabarbitone (c,d) on the disposition of mitozolomide in
plasma (a and c) and liver (b and d). The data shown were obtained from mice within the same experiment.
Error bars show s.d. of mean values which were obtained from 4 independent experiments. Experimental
points without error bars are mean values from 3 mice. ((0) saline; (0) phenobarbital).
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decomposes rapidly in alkaline conditions (Stevens
et al., 1984).
It is interesting that the presence of the ROS
tumour increases the plasma and tissue disposition
of mitozolomide. It has been shown that the
activities of hepatic drug metabolising enzymes are
depressed in tumour-bearing animals (Kato et al.,
1983). However, in the case of mitozolomide, one
would expect an increase in metabolising activity if
liver metabolism was responsible for the more rapid
disposition of mitozolomide. The altered pharmaco-
kinetics may be due to the ROS tumour causing an
induction of hepatic enzymes and we are continuing
to investigate this possibility.
That hepatic metabolism may be involved in the
decomposition of mitozolomide is suggested by the
reduction in the antitumour potency ofmitozolomide
after phenobarbitone pretreatment (Workman &
Lee, 1984). One may postulate that the induction
of liver microsomal enzymes by phenobarbitone
causes mitozolomide to be degraded to cytotoxic
products which do not reach the tumour in
sufficient concentrations for antitumour activity.
On the other hand, mitozolomide may be degraded
to non-toxic degradation products and the reduced
activity of the drug may then be due to lower con-
centrations of the parent drug reaching the
tumour. It is possible that the mixed function
oxidases catalyse the decomposition of mitozolo-
mide via the C-hydrolxylation of the chloroethyl
fragment by a similar mechanism to that observed
for the nitrosourea, (1-(2-chloroethyl)-3-(trans-4-
methylcyclohexyl)-1-nitrosourea (methyl CCNU)
(May et al., 1979).
Our studies demonstrate that pretreatment with
phenobarbitone decreased the plasma and tissue
availability of mitozolomide with a concomitant
increase in liver weight. Pentobarbitone, which also
induces microsomal enzymes had no effect on the
disposition of mitozolomide (Figure 3c,d). How-
ever, pentobarbitone is known to be a weaker
inducer of microsomal enzymes and we did not find
this barbiturate to cause an increase in liver weight
in mice.
Phenobarbitone is known to affect other
physiological factors; e.g., it increases both tissue
blood perfusion (Zannelli et al., 1975) and bile flow
(Rutishauser & Stone, 1975). Therefore the reduced
systemic availability of mitozolomide after pheno-
barbitone pretreatment may be due to an increase
in the rate of hepatic or renal clearance of the drug.
Although the major decomposition pathway of
mitozolomide is most probably via chemical
hydrolysis, further studies are required to elucidate
the effect of the presence of tumour and pheno-
barbitone pretreatment on the pharmacokinetics of
mitozolomide.
We thank the Cancer Research Campaign for their
support of this work.
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